tiprankstipranks
Healthy Extracts (HYEX)
OTHER OTC:HYEX
US Market
Want to see HYEX full AI Analyst Report?

Healthy Extracts (HYEX) AI Stock Analysis

7 Followers

Top Page

HYEX

Healthy Extracts

(OTC:HYEX)

Select Model
Select Model
Select Model
Neutral 48 (OpenAI - 5.2)
Rating:48Neutral
Price Target:
$1.00
▼(-49.24% Downside)
Action:ReiteratedDate:04/23/26
The score is driven primarily by improving financial fundamentals (revenue growth, higher gross margin, and recently positive operating/free cash flow) but is held back by continued net losses and uneven cash-flow strength. Technicals also weigh on the score, with the stock trading below major moving averages and negative MACD. Valuation provides limited support because the company is still loss-making and no dividend yield is available.
Positive Factors
Sustained Revenue Growth
Healthy Extracts has shown multi-year top-line expansion, roughly tripling revenue since 2020 with ~25.7% growth in 2025. Durable revenue expansion supports increased market penetration, better unit economics over time and gives management room to invest in product development and distribution for the next 2–6 months and beyond.
Negative Factors
Persistent Net Losses
Despite revenue and margin gains, negative net margins and operating losses mean the company still consumes capital to grow. Ongoing unprofitability limits retained earnings, depresses returns on equity and may require repeated external funding or dilution to sustain investment and scale over a multi-quarter horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Sustained Revenue Growth
Healthy Extracts has shown multi-year top-line expansion, roughly tripling revenue since 2020 with ~25.7% growth in 2025. Durable revenue expansion supports increased market penetration, better unit economics over time and gives management room to invest in product development and distribution for the next 2–6 months and beyond.
Read all positive factors

Healthy Extracts (HYEX) vs. SPDR S&P 500 ETF (SPY)

Healthy Extracts Business Overview & Revenue Model

Company Description
Healthy Extracts Inc., through its subsidiaries, researches, develops, and markets natural plant-based products in the United States and internationally. It offers heart health nutritional supplements; and neuro products under the KETONOMICS name ...

Healthy Extracts Financial Statement Overview

Summary
Revenue is growing and gross margin has improved, with recent positive operating and free cash flow in 2024–2025. However, the company remains unprofitable with negative net margins and cash generation is still uneven, limiting the financial strength score.
Income Statement
34
Negative
Balance Sheet
62
Positive
Cash Flow
50
Neutral
BreakdownDec 2025Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue4.51M3.11M2.49M2.25M1.47M
Gross Profit2.42M1.91M1.62M1.37M695.08K
EBITDA-791.66K-183.15K-2.24M-910.71K-1.88M
Net Income-881.12K-840.67K-2.47M-989.96K-2.04M
Balance Sheet
Total Assets27.82M2.38M2.64M2.78M3.03M
Cash, Cash Equivalents and Short-Term Investments146.94K112.02K19.44K65.65K222.10K
Total Debt2.64M941.90K1.13M593.52K342.62K
Total Liabilities3.80M1.97M1.68M902.79K558.84K
Stockholders Equity24.03M410.38K954.59K1.88M2.47M
Cash Flow
Free Cash Flow146.22K281.97K-415.75K-342.95K-997.30K
Operating Cash Flow165.52K281.97K-415.75K-334.96K-901.30K
Investing Cash Flow56.30K0.000.00-7.99K-96.00K
Financing Cash Flow-186.91K-189.39K369.54K239.52K1.16M

Healthy Extracts Technical Analysis

Technical Analysis Sentiment
Positive
Last Price1.97
Price Trends
50DMA
2.07
Positive
100DMA
2.00
Positive
200DMA
2.06
Positive
Market Momentum
MACD
-0.07
Negative
RSI
59.32
Neutral
STOCH
30.02
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYEX, the sentiment is Positive. The current price of 1.97 is above the 20-day moving average (MA) of 1.85, below the 50-day MA of 2.07, and below the 200-day MA of 2.06, indicating a bullish trend. The MACD of -0.07 indicates Negative momentum. The RSI at 59.32 is Neutral, neither overbought nor oversold. The STOCH value of 30.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYEX.

Healthy Extracts Risk Analysis

Healthy Extracts disclosed 11 risk factors in its most recent earnings report. Healthy Extracts reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 2 New Risks
1.
An active trading market for our Common Stock may not develop and you may not be able to resell your shares at or above the public offering price. Q4, 2023
2.
We have broad discretion in the use of our cash, and may not use it effectively. Q4, 2023

Healthy Extracts Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
$67.75M-10.54-10.54%17.57%58.90%
55
Neutral
$78.19M0.56-19.05%449.95%70.24%
54
Neutral
$35.07M-14.82-15.64%-31.76%-451.65%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
48
Neutral
$21.11M-22.96-18.78%44.93%37.70%
45
Neutral
$27.37M-0.62-107.16%-8.91%-219.62%
44
Neutral
$18.14M-0.37-63.82%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
HYEX
Healthy Extracts
1.25
-2.37
-65.47%
RMTI
Rockwell Med
0.89
-0.30
-25.21%
SCYX
SCYNEXIS
0.98
0.02
1.55%
AYTU
Aytu BioScience
2.55
1.25
96.15%
CPIX
Cumberland Pharmaceuticals
4.53
0.06
1.34%
COSM
Cosmos Holdings
0.36
-0.10
-21.88%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Apr 23, 2026